Source comparison
Comparison Table — Tesamorelin vs Exogenous GH for Lipodystrophy
Telehealth clinicians researching tesamorelin often ask whether exogenous recombinant GH (somatropin) would achieve similar or superior VAT reduction with fewer logistical constraints. The answer is mechanistically no. And the following comparison explains why
This comparison does not assign a generated winner or score.
- Telehealth clinicians researching tesamorelin often ask whether exogenous recombinant GH (somatropin) would achieve similar or superior VAT reduction with fewer logistical constraints. The answer is mechanistically no. And the following comparison explains why the preserved feedback loop matters more than dosing convenience.
- Mechanism
- Stimulates pulsatile endogenous GH release from pituitary
- Bypasses pituitary, provides exogenous GH directly
- Tesamorelin preserves negative feedback via IGF-1; somatropin does not
- IGF-1 Elevation
- 1.5–2.0× baseline (self-limiting)
- 2.5–4.0× baseline (dose-dependent, no ceiling)
- Lower IGF-1 peaks reduce acromegaly risk and insulin resistance
- FDA Approval for HIV Lipodystrophy
- Yes (Egrifta approved 2010)
- No (off-label use only)
- Insurance coverage significantly better for tesamorelin in this indication
- Dosing Frequency
- Once daily subcutaneous injection
- No practical difference in administration burden
- Cost (30-day supply)
- $4,000–$5,500 (branded Egrifta)
- $1,200–$2,800 (generic somatropin, dose-dependent)
- Somatropin cheaper but not covered for lipodystrophy without off-label approval
- Insulin Resistance Risk
- Low (IGF-1-mediated insulin sensitization in muscle)
- Moderate to high (direct GH effect on hepatic glucose output)
- Tesamorelin safer for patients with prediabetes or metabolic syndrome
- Tesamorelin is the evidence-based first-line therapy for HIV-associated lipodystrophy because it reduces VAT without the metabolic and endocrine risks of exogenous GH. Somatropin should be reserved for true GH deficiency, not lipodystrophy management.